Abstract: The present invention relates to immunoconjugates for specific induction of T cell cytotoxicity against a target cell, comprising at least one T cell response eliciting peptide that is presentable via MHC class I coupled to a target cell binding moiety via a cleavable bond and methods of their production and uses thereof.

Abstract: The current invention is directed to a method for obtaining a nucleic acid encoding an immunoglobulin variable domain from a single cell comprising the following steps: performing a first polymerase chain reaction with three to six 5?-primer and one 3?-primer, performing with the product of the first polymerase chain reaction a second polymerase chain reaction with thirteen to sixteen 5?-primer and one 3?-primer, whereby the distance of the binding locations of the primer employed in the second polymerase chain reaction is reduced compared to the first polymerase chain reaction.

Abstract: The current invention is directed to a method for obtaining a nucleic acid encoding an immunoglobulin variable domain from a single cell comprising the following steps: —performing a first polymerase chain reaction with three to six 5?-primer and one 3?-primer, performing with the product of the first polymerase chain reaction a second polymerase chain reaction with thirteen to sixteen 5?-primer and one 3?-primer, whereby the distance of the binding locations of the primer employed in the second polymerase chain reaction is reduced compared to the first polymerase chain reaction.

Abstract: The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: Herein is reported a method for a multiplex one tube real-time reverse-transcriptase gene-specific polymerase chain reaction for the amplification and quantification of cognate IgG heavy and light chains encoding nucleic acids (human IgG isotype) from a single cell.

Abstract: The present invention relates to antibodies against human CDCP1 binding to the same epitope as CUB4 (Deposition No. DSM ACC2551) for the treatment of cancer.

Abstract: The current invention is related to a method for the production of a human monoclonal antibody from a immunodeficient non-human animal, said method comprising contacting a new borne immunodeficient non-human animal with a human fetal liver stem cell (FL cell) to generate an immune transplanted non-human animal (reconstituted animal), subsequently contacting said reconstituted animal with a antigen, collecting from said reconstituted animal a human cell producing human antibody against said antigen, and isolating said antibody from said antibody producing cell.

Abstract: The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The current invention is related to a method for the production of a human monoclonal antibody from a immundeficient non-human animal, said method comprising contacting a new borne immunodeficient non-human animal with a human fetal liver stem cell (FL cell) to generate an immune transplanted non-human animal (reconstituted animal), subsequently contacting said reconstituted animal with a antigen, collecting from said reconstituted animal a human cell producing human antibody against said antigen, and isolating said antibody from said antibody producing cell.

Abstract: The current invention is directed to a method for obtaining a nucleic acid encoding an immunoglobulin variable domain from a single cell comprising the following steps:—performing a first polymerase chain reaction with three to six 5?-primer and one 3?-primer, performing with the product of the first polymerase chain reaction a second polymerase chain reaction with thirteen to sixteen 5?-primer and one 3?-primer, whereby the distance of the binding locations of the primer employed in the second polymerase chain reaction is reduced compared to the first polymerase chain reaction.

Abstract: The present invention relates to antibodies against human CDCP1 binding to the same epitope as CUB4 (Deposition No. DSM ACC2551) for the treatment of cancer.

Abstract: The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The current invention is related to a method for the production of a human monoclonal antibody from a immunodeficient non-human animal, said method comprising contacting a new borne immunodeficient non-human animal with a human fetal liver stem cell (FL cell) to generate an immune transplanted non-human animal (reconstituted animal), subsequently contacting said reconstituted animal with a antigen, collecting from said reconstituted animal a human cell producing human antibody against said antigen, and isolating said antibody from said antibody producing cell.

Abstract: The current invention is related to a method for the production of a human monoclonal antibody from a immundeficient non-human animal, said method comprising contacting a new borne immunodeficient non-human animal with a human fetal liver stem cell (FL cell) to generate an immune transplanted non-human animal (reconstituted animal), subsequently contacting said reconstituted animal with a antigen, collecting from said reconstituted animal a human cell producing human antibody against said antigen, and isolating said antibody from said antibody producing cell.